4th Annual CEO Remuneration Report – Wexford Hayes
31 January 2019 This 4th annual CEO Remuneration report reviews the remuneration of the top 100 public companies listed on the Australian Securities Exchange for the Health Care & Biotechnology Sector. The report provides insight into remuneration in…
Sienna furthers its Global Expansion with Distributor for the Republic of Korea
22 January 2019 Highlights: Mirax Corporation appointed as exclusive distributor for Korea Important expansion of commercial opportunity in high-growth Asian IVD market Sienna Cancer Diagnostics Ltd a medical technology company developing and commercialising innovative cancer related tests, continues…
Super Charging The Immune System to Fight Cancer
22 January 2019 Innovative immunotherapies for cancer are a step closer to reality thanks to an agreement between Australia’s Cartherics Pty Ltd and Seoul-based ToolGen Inc. The agreement, signed in Melbourne on 21 January 2019, enables the companies…
Imagion Biosystems teams with Planet Innovation for MagSense™ instrument development
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, and Planet Innovation, a healthtech innovation and commercialization company, are pleased to announce that they have entered into a…
Victoria leads the way with NHMRC funding
13 December 2018 The announcement of the latest round of NHMRC funding yesterday has again highlighted the strength of Melbourne’s medical research community. Continuing the state’s unbroken record of receiving more than 40% of NHMRC competitive grant funding,…
Design + Industry is now ISO 13485:2016 certified
BioMelbourne Network member Design + Industry (D+I) is proud to announce that they have achieved ISO 13485:2016 certification — the culmination of a four-year effort and recognition of their commitment to design and engineering excellence in the development…
Board announcement: CEO resignation
6 December 2018 Message from the Chair On behalf of the Board of BioMelbourne Network, I advise our Members, partners and associates that our CEO, Dr Krystal Evans, has tendered her resignation. Krystal will leave us in the…
2019 ARCS Annual Conference: call for session and program proposals extended
Interested parties from industry, research institutions, government and academia involved in development through to commercialisation of therapeutics (from bench to bedside) are invited to submit session proposals and program suggestions for the 2019 ARCS Annual Conference to be…
BioEYES looking for industry partners
3 December 2018 BioEYES Australia is a science outreach program that covers curricula in genetics, cell biology and developmental biology, but more importantly excites students about the thrill of scientific discovery. Over a 1 week incursion, students set…
Nominations open for 2019 Women in Leadership Awards
Do you know a woman who is making an outstanding contribution to the health and biotech sector? Why not nominate her for a 2019 BioMelbourne Network Women in Leadership Award? Awards are made in three categories, recognising women in…
Victoria’s health industry welcomes Andrews government
30 November 2018 On behalf of its members, BioMelbourne Network congratulates the Hon Daniel Andrews MP and the Victorian Labor party on their re-election at the 2018 state election. BioMelbourne Network CEO Dr Krystal Evans welcomes the opportunity…
WILD Program launches within the Victorian STEM sector
22 November 2018 The Women in Leadership Development (WILD) Program announced its launch yesterday, with the first intake of women in the science, technology, engineering and maths (STEM) sector. The WILD Program helps build on the qualifications, skills…
